The purpose of this study is to evaluation the tolerability of an add-on therapy with
artesunate with a duration of 4 weeks in patients with advanced breast cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Heidelberg University
Collaborators:
Dafra Pharma Dafra Pharma Research & Development BVBA H. W. & J. Hector-Stiftung, Weinheim Hector-Stiftung HEIFAN-Heidelberger Förderverein d. Ambulanz f. Naturheilkunde eV, Heidelberg, Germany Monika-Kutzner Stiftung, Berlin, Germany